Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

UVA scientists find blueprint for combating human disease using DNA clad in near-indestructible armor

UVA scientists find blueprint for combating human disease using DNA clad in near-indestructible armor

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Sandia biosciences technologies could soon find their way into doctors' offices

Sandia biosciences technologies could soon find their way into doctors' offices

Bioethics Commission makes recommendations on preparedness for public health emergencies

Bioethics Commission makes recommendations on preparedness for public health emergencies

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Investigators develop microbiome map of New York City subway system

Investigators develop microbiome map of New York City subway system

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Soligenix closes previously announced registered public offering

Soligenix closes previously announced registered public offering

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

IU Bloomington biologists to receive funding from NSF’s Dimensions of Biodiversity Program

IU Bloomington biologists to receive funding from NSF’s Dimensions of Biodiversity Program

Pharmaceutical industry withdraws from the antibiotic space

Pharmaceutical industry withdraws from the antibiotic space

LLNL scientists issued patent for producing antimicrobial compounds to fight superbugs

LLNL scientists issued patent for producing antimicrobial compounds to fight superbugs

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers